Sealantium Medical Ltd.

This Phase I/II randomized, controlled, multicenter study aimed to evaluate the safety and efficacy of sFilm-FS compared to Tachosil® in patients undergoing elective liver surgery requiring hemostasis at the liver surface. sFilm-FS is a new fibrin sealant patch, coating on a biodegradable tri-block polymeric film. The trial included 33 patients randomized 1:1 to receive sFilm-FS or Tachosil®. While most patients underwent liver resection, a subset underwent other hepatic surgical interventions. Safety was the primary outcome, including treatment-emergent adverse events, coagulopathies, and intraoperative blood loss. Efficacy was assessed as secondary endpoints by the time to hemostasis and hemostasis at 2, 3, 5, 7, and 10 ​min from product application. Hemostasis was defined as the absence of bleeding at the target bleeding site within 10 ​min. Both treatments were well tolerated, with no significant differences in adverse events. All patients achieved hemostasis within 10 ​min. The median time to hemostasis was 2 ​min for sFilm-FS and 3 ​min for Tachosil®. sFilm-FS is a promising, well tolerated, fibrin sealant patch, offering the potential for a superior Fibrin Sealant patch that could improve surgical outcomes. Further studies are recommended to validate these findings in larger populations.